News
Public · Published
Alembic Pharmaceuticals Q2 Results: Shares jump 20% after profit rises 81%; US business grows 77%
Alembic Pharmaceuticals reported September-quarter revenue of ₹2,603 crore, up 36.3% year on year, and profit after tax of ₹335 crore, up 81.1%. US formulations revenue increased 77% to ₹1,003 crore, and the company launched three products in the US market during the quarter.
Published:
Updated:
What happened
Alembic Pharmaceuticals reported September-quarter revenue of ₹2,603 crore, up 36.3% year on year, and profit after tax of ₹335 crore, up 81.1%. US formulations revenue increased 77% to ₹1,003 crore, and the company launched three products in the US market during the quarter.
Confirmed
Global impact / market context
Higher revenue and profit indicate stronger business performance, while the US segment’s growth provides a substantial contribution to sales. If growth continues, it could support earnings and cash available for investment; however, the article gives no detail on whether these results will persist.
Analyst inference
The reported gains were broad: India branded sales grew 14%, ex-US sales 12%, and active pharmaceutical ingredients sales 39%, while the US led at 77%. EBITDA, a measure of operating earnings before interest, taxes and certain non-cash costs, rose 78.7%; its share of revenue also increased.
Confirmed
What to watch
- Whether Alembic sustains US formulations growth after launching three products in the quarter; the article does not say how much those launches contributed to sales. Analyst inference
- Whether the company receives further abbreviated new drug application approvals, regulatory clearances to sell generic medicines; it received one this quarter, bringing the total to 245. Analyst inference
- Whether revenue and profit growth continue in later quarters, particularly across US and other businesses; the supplied article provides results only for the September quarter. Analyst inference
Evidence
- Original source link unavailable